[
  {
    "ts": null,
    "headline": "Top Stock Reports for Eli Lilly, Oracle & Procter & Gamble",
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly, Oracle, and Procter & Gamble, as well as a micro-cap stock, Comstock.",
    "url": "https://finnhub.io/api/news?id=9622374136570124133b7c3eea222ee372c1ad715838bd4eedfe28ebd7b958ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756418340,
      "headline": "Top Stock Reports for Eli Lilly, Oracle & Procter & Gamble",
      "id": 136569047,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly, Oracle, and Procter & Gamble, as well as a micro-cap stock, Comstock.",
      "url": "https://finnhub.io/api/news?id=9622374136570124133b7c3eea222ee372c1ad715838bd4eedfe28ebd7b958ce"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Are ‘Priced at Panic Levels.’ It’s Time to Buy.",
    "summary": "They’re bargains right now, according to two key measures. Expert Jim Paulsen won’t venture a guess when the prices will recover.",
    "url": "https://finnhub.io/api/news?id=fd4eb00bd44731e8992d76e1c0275a4fb0d913031c03485e261f075be376c8b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756406460,
      "headline": "Healthcare Stocks Are ‘Priced at Panic Levels.’ It’s Time to Buy.",
      "id": 136563715,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "They’re bargains right now, according to two key measures. Expert Jim Paulsen won’t venture a guess when the prices will recover.",
      "url": "https://finnhub.io/api/news?id=fd4eb00bd44731e8992d76e1c0275a4fb0d913031c03485e261f075be376c8b7"
    }
  },
  {
    "ts": null,
    "headline": "Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC",
    "summary": "Equillium, Inc. raises $50M to advance EQ504, a novel AhR modulator for ulcerative colitis. Phase 1 trials begin mid-2026. Click for more on EQ stock prospects.",
    "url": "https://finnhub.io/api/news?id=05298a6821a423e89829c846031602b35461c0b7ef1f4908cbbbf3f55e837930",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756402506,
      "headline": "Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC",
      "id": 136564670,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2228863093/image_2228863093.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Equillium, Inc. raises $50M to advance EQ504, a novel AhR modulator for ulcerative colitis. Phase 1 trials begin mid-2026. Click for more on EQ stock prospects.",
      "url": "https://finnhub.io/api/news?id=05298a6821a423e89829c846031602b35461c0b7ef1f4908cbbbf3f55e837930"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Reports Positive Outcomes for Verzenio in Breast Cancer Trial",
    "summary": "Eli Lilly (LLY) announced positive results from the Phase 3 MonarchE trial, demonstrating Verzenio's effectiveness in treating early breast cancer, which has reinforced confidence in the company's oncology portfolio. Meanwhile, the Phase 3 ATTAIN-2 trial for orforglipron showed promising results for weight loss treatments. Amid these developments, Eli Lilly's stock rose 3% last week, aligning with broader market gains as the S&P 500 and Nasdaq achieved record highs. The company's...",
    "url": "https://finnhub.io/api/news?id=d9463cf969c4d43b4528ebf64862637708fb4d93fa1291049b745959d78c5e44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756402485,
      "headline": "Eli Lilly (LLY) Reports Positive Outcomes for Verzenio in Breast Cancer Trial",
      "id": 136563716,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) announced positive results from the Phase 3 MonarchE trial, demonstrating Verzenio's effectiveness in treating early breast cancer, which has reinforced confidence in the company's oncology portfolio. Meanwhile, the Phase 3 ATTAIN-2 trial for orforglipron showed promising results for weight loss treatments. Amid these developments, Eli Lilly's stock rose 3% last week, aligning with broader market gains as the S&P 500 and Nasdaq achieved record highs. The company's...",
      "url": "https://finnhub.io/api/news?id=d9463cf969c4d43b4528ebf64862637708fb4d93fa1291049b745959d78c5e44"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Verzenio boosts OS in breast cancer as Novartis rivalry heats up",
    "summary": "The positive Phase III topline results could give Lilly an advantage against rival CDK4/6 inhibitor, Kisqali.",
    "url": "https://finnhub.io/api/news?id=df65a7a123ce62d2479d6b21923a7ff7c5a4d841387c794d6e23a9db2b30c4fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756393849,
      "headline": "Eli Lilly’s Verzenio boosts OS in breast cancer as Novartis rivalry heats up",
      "id": 136560798,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The positive Phase III topline results could give Lilly an advantage against rival CDK4/6 inhibitor, Kisqali.",
      "url": "https://finnhub.io/api/news?id=df65a7a123ce62d2479d6b21923a7ff7c5a4d841387c794d6e23a9db2b30c4fb"
    }
  },
  {
    "ts": null,
    "headline": "2 Growth Stocks That Could Be Worth $1 Trillion in 5 Years",
    "summary": "These two longtime market leaders should continue to perform well.",
    "url": "https://finnhub.io/api/news?id=940ed0a9a05b5d73504f52a9a1da73f837f81ad32f7414fc2ea5ed355f0140fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756388700,
      "headline": "2 Growth Stocks That Could Be Worth $1 Trillion in 5 Years",
      "id": 136557612,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These two longtime market leaders should continue to perform well.",
      "url": "https://finnhub.io/api/news?id=940ed0a9a05b5d73504f52a9a1da73f837f81ad32f7414fc2ea5ed355f0140fe"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia CEO praises open-source AI as enterprises deploy GPU servers",
    "summary": "“Open-source models are opening up large enterprises, SaaS companies, industrial companies, robotics companies to now join the AI revolution,” Jensen Huang said.",
    "url": "https://finnhub.io/api/news?id=de33a02ea6b630d4a59143f4d217eff4a7d354f5d625710d113e652458dab538",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756388292,
      "headline": "Nvidia CEO praises open-source AI as enterprises deploy GPU servers",
      "id": 136564782,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "“Open-source models are opening up large enterprises, SaaS companies, industrial companies, robotics companies to now join the AI revolution,” Jensen Huang said.",
      "url": "https://finnhub.io/api/news?id=de33a02ea6b630d4a59143f4d217eff4a7d354f5d625710d113e652458dab538"
    }
  },
  {
    "ts": null,
    "headline": "Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?",
    "summary": "Pfizer braces for patent losses, IRA pressure and COVID uncertainty, but cost cuts and key drugs may still support profit growth.",
    "url": "https://finnhub.io/api/news?id=a72c3586afaa7ece6e70f2b2971d4a5c05086bda0c20505f68b074db1b0e3903",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756387320,
      "headline": "Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?",
      "id": 136560799,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer braces for patent losses, IRA pressure and COVID uncertainty, but cost cuts and key drugs may still support profit growth.",
      "url": "https://finnhub.io/api/news?id=a72c3586afaa7ece6e70f2b2971d4a5c05086bda0c20505f68b074db1b0e3903"
    }
  },
  {
    "ts": null,
    "headline": "Pharmacies turn patients away as Mounjaro shortages hit Britain",
    "summary": "Pharmacies are being forced to turn away patients after the manufacturer of the weight-loss drug Mounjaro stopped selling to the UK.",
    "url": "https://finnhub.io/api/news?id=ea79eb97c15495edcfbb9c3cd3ffad981bd94853128a1d0ba3947edb9a415c46",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756384410,
      "headline": "Pharmacies turn patients away as Mounjaro shortages hit Britain",
      "id": 136557746,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pharmacies are being forced to turn away patients after the manufacturer of the weight-loss drug Mounjaro stopped selling to the UK.",
      "url": "https://finnhub.io/api/news?id=ea79eb97c15495edcfbb9c3cd3ffad981bd94853128a1d0ba3947edb9a415c46"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure",
    "summary": "Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment. Can it make a comeback?",
    "url": "https://finnhub.io/api/news?id=c37ea4279111ca34f3f9dc8a53b1e1edb48d83240eee46948b66d07792df8d91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756382405,
      "headline": "Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure",
      "id": 136557747,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment. Can it make a comeback?",
      "url": "https://finnhub.io/api/news?id=c37ea4279111ca34f3f9dc8a53b1e1edb48d83240eee46948b66d07792df8d91"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: In The Eye Of The Drug Pricing Storm - Expect Volatility, And Buy",
    "summary": "Eli Lilly's GLP-1 drugs fuel massive growth, with potential $60bn+ annual revenue. Check out why I remain bullish long term on LLY stock.",
    "url": "https://finnhub.io/api/news?id=e148f60246a8271aa29e30340c59e76c8252c922dac359d5c25be401fe58b164",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756381875,
      "headline": "Eli Lilly: In The Eye Of The Drug Pricing Storm - Expect Volatility, And Buy",
      "id": 136559412,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/490484368/image_490484368.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's GLP-1 drugs fuel massive growth, with potential $60bn+ annual revenue. Check out why I remain bullish long term on LLY stock.",
      "url": "https://finnhub.io/api/news?id=e148f60246a8271aa29e30340c59e76c8252c922dac359d5c25be401fe58b164"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Orals Unlock The Next Wave Of Obesity Drug Adoption",
    "summary": "Eli Lilly's orforglipron outshines Novo Nordisk's oral semaglutide with efficacy & scalability, promising growth in obesity & diabetes markets.",
    "url": "https://finnhub.io/api/news?id=ca4aec7f7269123b138f760b211981c276e845cd6b660c7adebee5ba8fbf3235",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756379229,
      "headline": "Eli Lilly: Orals Unlock The Next Wave Of Obesity Drug Adoption",
      "id": 136558450,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2214373984/image_2214373984.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's orforglipron outshines Novo Nordisk's oral semaglutide with efficacy & scalability, promising growth in obesity & diabetes markets.",
      "url": "https://finnhub.io/api/news?id=ca4aec7f7269123b138f760b211981c276e845cd6b660c7adebee5ba8fbf3235"
    }
  },
  {
    "ts": null,
    "headline": "Novo strikes RNA drug deal with startup Replicate",
    "summary": "The agreement provides research funding for Replicate and up to $550M in payments to develop medicines for diseases including obesity and diabetes.",
    "url": "https://finnhub.io/api/news?id=b4ae7530231a77ab97aae1191e34ec88d46ac197a96162216559a08f74c71862",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756377360,
      "headline": "Novo strikes RNA drug deal with startup Replicate",
      "id": 136557748,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The agreement provides research funding for Replicate and up to $550M in payments to develop medicines for diseases including obesity and diabetes.",
      "url": "https://finnhub.io/api/news?id=b4ae7530231a77ab97aae1191e34ec88d46ac197a96162216559a08f74c71862"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly said it would bring 750 jobs to Kenosha County. Contract with state calls for 560",
    "summary": "The contract between Eli Lilly and the WEDC shows what benchmarks the company needs to hit to be eligible for the full $100 million of tax credits.",
    "url": "https://finnhub.io/api/news?id=87a41267e76d4926e48bb063733006d2197cc7ea3cfbe5b8dcdaff691979768b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756375438,
      "headline": "Eli Lilly said it would bring 750 jobs to Kenosha County. Contract with state calls for 560",
      "id": 136557749,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The contract between Eli Lilly and the WEDC shows what benchmarks the company needs to hit to be eligible for the full $100 million of tax credits.",
      "url": "https://finnhub.io/api/news?id=87a41267e76d4926e48bb063733006d2197cc7ea3cfbe5b8dcdaff691979768b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Why I'm Pairing It With My Novo Position",
    "summary": "Eli Lilly and Company drives growth with innovative diabetes and obesity drugs, expanding portfolios, and R&D strength. Click for more on LLY stock prospects.",
    "url": "https://finnhub.io/api/news?id=cf26d9648e178d60381e053c920ab170c662198ada13d54d457593367f919868",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756369130,
      "headline": "Eli Lilly: Why I'm Pairing It With My Novo Position",
      "id": 136557344,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2227136231/image_2227136231.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company drives growth with innovative diabetes and obesity drugs, expanding portfolios, and R&D strength. Click for more on LLY stock prospects.",
      "url": "https://finnhub.io/api/news?id=cf26d9648e178d60381e053c920ab170c662198ada13d54d457593367f919868"
    }
  }
]